Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Cash from Operations (2018 - 2025)

Historic Cash from Operations for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to -$1.2 million.

  • BioNexus Gene Lab's Cash from Operations rose 2280.49% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.7 million, marking a year-over-year increase of 1207.59%. This contributed to the annual value of -$2.2 million for FY2024, which is 2261.25% down from last year.
  • BioNexus Gene Lab's Cash from Operations amounted to -$1.2 million in Q3 2025, which was up 2280.49% from -$737907.0 recorded in Q2 2025.
  • Over the past 5 years, BioNexus Gene Lab's Cash from Operations peaked at $483007.0 during Q4 2021, and registered a low of -$1.6 million during Q3 2024.
  • In the last 5 years, BioNexus Gene Lab's Cash from Operations had a median value of -$116518.0 in 2023 and averaged -$331312.3.
  • In the last 5 years, BioNexus Gene Lab's Cash from Operations surged by 11181.03% in 2021 and then plummeted by 272195.78% in 2024.
  • Over the past 5 years, BioNexus Gene Lab's Cash from Operations (Quarter) stood at $483007.0 in 2021, then dropped by 1.3% to $476739.0 in 2022, then crashed by 264.14% to -$782526.0 in 2023, then surged by 109.99% to $78203.0 in 2024, then tumbled by 1682.38% to -$1.2 million in 2025.
  • Its Cash from Operations was -$1.2 million in Q3 2025, compared to -$737907.0 in Q2 2025 and -$824072.0 in Q1 2025.